A Science and Technology Blog
In the case of AstraZeneca, effectiveness against hospitalisation after full vaccination was 92%, while it was 96% in the case of Pfizer. The results have been posted as a preprint.…
In an email, Dr. Gagandeep Kang, Professor of Microbiology at CMC Vellore and Dr. Chandrakant Lahariya, physician-epidemiologist and a vaccines and health systems expert discuss the ethical and structural challenges…
The study has been published in the journal Mayo Clinic Proceedings. “Our study shows that COVID-19 vaccines have a great benefit in reducing infection and severity of disease. Vaccination helps…
The study evaluated the neutralisation potential in people vaccinated with Covaxin and found that there was a 3- and 2.7-fold reduction in neutralisation titers against the beta (B.1.351) and delta…
The seropositivity rates and the median antibody titre against spike protein was “significantly higher” in those vaccinated with Covishield compared with Covaxin, according to a preprint posted in medRxiv. Preprints…
With the alpha (B.1.1.7) and delta (B.1.617.2) variants widely present across the country, and the possibility of new variants with higher transmissive ability getting imported or emerging in India cannot…
India approved Covishield with an interval of four-six weeks between two doses despite the MHRA approving AstraZeneca with a 4-12 weeks gap and JCVI approving a 12-week prime-boost interval. What…
According to the PIB release, the myth was that the Centre wasn’t taking any step to vaccinate children. Clarifying this, Dr. Paul said: “As of now, no country in the…
